Aim: The objective of this study was to explore the cost-effectiveness of D-dimer biomarker and the societal value (headroom) of a hypothetical perfect biomarker for risk assessment and subsequent treatment stratification of prophylactic treatment for peripheral arterial disease (PAD). Patients & methods: Decision analytic modeling. Results: Use of the D-dimer biomarker to prescribe oral anticoagulants in the high-risk subset of patients is a cost-effective healthcare intervention. The headroom (societal willingness to pay multiplied by incremental quality-adjusted life years) available for the hypothetical perfect biomarker amounted to €83,877. Conclusion: D-dimer-based PAD risk assessment and treatment tailoring is cost effective. Identification of high-risk PAD patients and prescription of oral anticoagulants could potentially save substantial costs and improve chances of survival for high-risk PAD patients. However, further research of risk stratifying biomarkers test accuracy is needed to support and strengthen the results of this modeling study.

, , , ,,
Biomarkers in Medicine
Erasmus School of Health Policy & Management (ESHPM)

Vaidya, A, Joore, M.A, Ten Cate-Hoek, A.J, ten Cate, H, & Severens, J.L. (2014). Cost-effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients. Biomarkers in Medicine, 8(8), 989–999. doi:10.2217/bmm.14.45